Global Pediatric
Clinical Trials Market, by Clinical Trial Phase (Pre-clinical, Phase I,
Phase II, and Phase III), by Study Design (Interventional (Randomized Trial,
Non-randomized Trial, and Crossover Trial), and Observational), by Medical
Condition (Neuropsychiatric Conditions, Infectious Diseases, Maternal and
Perinatal Conditions, Respiratory Diseases, Cardiovascular Diseases, Cancer,
Digestive Diseases, Diabetes, Nutritional Deficiencies, and Others), and by
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa), is estimated to be valued at US$ 12,571.7 million in 2020 and is
expected to exhibit a CAGR of 9.0% over the forecast period (2020-2027), as
highlighted in a new report published by Coherent Market Insights.
Major companies (and more
recently medium sized companies) are actively entering into strategic
partnerships and collaborations with a limited number of CROs to increase
efficiency. The CRO industry and in particular, large CROs with global
capabilities, considerable scientific knowledge, and expertise are often able
to perform the needed services with greater focus and at a lower cost than the
client could perform internally. For instance, in April 2017, Charles River
entered into a strategic collaboration with Nimbus Therapeutics aimed at
advancing new programs in immunology, metabolic disorders, and oncology from
the discovery phase through to Investigational New Drug (IND) submission. In
October 2018, the pharmaceuticals division of Roche selected IQVIA’s commercial
technology suite for deployment across more than 100 markets.
Moreover, in February 2020, WPD
Pharmaceuticals Inc. entered into a collaboration agreement with CNS
Pharmaceuticals, Inc., a biotechnology company specializing in the development
of novel treatments for primary and metastatic brain and central nervous system
tumors, to initiate a Phase I clinical trial for Berubicin in pediatric brain
cancer, in Poland. This trend is likely to be followed by mid-size pharma and
biotech companies during the forecast period
Global Pediatric Clinical Trials
Market – Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 pandemic has
drastically affected clinical trials. Many trials have paused enrollment and researchers
are facing multiple challenges associated with setting up remote visits, and
performing laboratory and other study assessments.
According to a survey conducted
by Medidata Solutions, Inc. (an American technology company, which develops and
markets software as a service for clinical trials), on April 23, 2020, 63% of
survey respondents reported that they stopped recruiting new patients for
ongoing clinical trials and 43% of the respondents have postponed their studies
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/397
The following factors are
considered for pediatric clinical drug trials:
Enrollment of patients who are
more susceptible to severe COVID-19 infections such as pediatric oncology
patients, have been restricted
Patients who are suffering from
infections, including those who have COVID-19 symptoms or were exposed to
COVID-19 suffering people, are excluded from participation in pediatric studies
associated with immunosuppressive therapies
Due to the lockdown, patients are
unable to come to the site for final phases of ongoing pediatric studies,
hence, they have to be kept in the study and remain on the study drug for a
longer duration than expected. Therefore, safety must be followed and evaluated
for patients who are receiving prolonged treatment, as there may be positive or
negative effect of the investigational drugs on the patients.
Browse 36 Market Data Tables and
37 Figures spread through 313 sPages and in-depth TOC on “Global Pediatric
Clinical Trials Market, by Clinical Trial Phase (Pre-clinical, Phase I, Phase
II, and Phase III), by Study Design (Interventional (Randomized Trial,
Non-randomized Trial, and Crossover Trial), and Observational), by Medical
Condition (Neuropsychiatric Conditions, Infectious Diseases, Maternal and
Perinatal Conditions, Respiratory Diseases, Cardiovascular Diseases, Cancer,
Digestive Diseases, Diabetes, Nutritional Deficiencies, and Others), and by
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa).
The market is expected to gain
significant traction during the forecast period, as various contract research
organizations offer advanced pharmaco metric modeling and clinical trial
simulation technologies, juvenile formulation, and toxicology services across
pediatric indications. Players in the clinical research industry are engaged in
adoption of inorganic growth strategies to expand their capabilities to conduct
pre-clinical studies. For instance, in March 2020, Altasciences, a CRO in the
U.S. and Canada engaged in early stage drug development, entered into a
partnership agreement with Amador Bioscience, a CRO in China and the U.S., to
expand and promote drug development processes such as preclinical studies and
to conduct early-stage clinical programs in China and North America.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/pediatric-clinical-trials-market-397
Key Takeaways of the Global
Pediatric Clinical Trials Market:
The global pediatric clinical
trials market is expected to exhibit a CAGR of 9.0% over the forecast period,
owing to robust product pipeline and increasing approval of new pediatric drugs
Among clinical trial phase, the
pre-clinical segment is expected to hold a dominant position in the pediatric
clinical trials market in 2020, owing to safety and efficacy concerns regarding
new molecules or drugs, as every new molecule must go through pre-clinical
study
Among study design type,
randomized trial segment is expected to hold a dominant position in the
pediatric clinical trials market in 2020, as randomized trial study design
eliminates the chance of bias in clinical trials and is considered as the most
favorable study design
Among medical condition,
neuropsychiatric conditions segment is expected to hold dominant position in
the pediatric clinical trials market in 2020, owing to increasing number of
mental disorders in children and adolescents. Mental disorders mainly affect
children before the age of 14 years.
Key players operating in the
global pediatric clinical trials market include Syneos Health Inc., IQVIA
Holdings, Inc., Charles River Laboratories International Inc., Covance Inc.,
ICON plc, Pharmaceutical Product Development, LLC, Genentech (F. Hoffmann-La
Roche AG), Pfizer, Inc., Bristol - Myers Squibb, GlaxoSmithKline plc., Sanofi
S.A., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Takeda
Pharmaceutical Company Limited, and Vertex Pharmaceuticals Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/397
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
